A Phase 3 interventional study of Lenalidomide and Docetaxel in Prostate Cancer, sponsored by Celgene. Completed at 210 sites in 21 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-04.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing lenalidomide in Prostatic Neoplasms — none open to participants now, none under way, none of them phase 3. Lenalidomide · Prostatic Neoplasms.
Among the 10 studies testing lenalidomide in Prostatic Neoplasms, this one has the largest enrollment, is one of 3 that started in 2009, is the only one in phase 3, and was the 8th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →None of the 10 studies testing lenalidomide in Prostatic Neoplasms is open now. The open studies under Prostatic Neoplasms, anywhere →
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 1
First in 2005; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,059 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 37 across the 10 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
30 studies in Prostatic Neoplasms by Bristol-Myers Squibb: 2 open now, 3 under way, 1 of them phase 3. Of 27 finished, 12 (44%) have results posted.
Among the 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb, this one is the 2nd largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2009, is one of 6 in phase 3, and was the 17th registered.
Bristol-Myers Squibb’s Prostatic Neoplasms studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing lenalidomide in Prostatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 30 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine whether lenalidomide is safe and effective for use in combination with docetaxel and prednisone for the treatment of subjects with metastatic Castrate-Resistant Prostate Cancer.
The addition of lenalidomide to docetaxel and prednisone is proposed to increase the life expectancy of these subjects.
In November 2011, the Data Monitoring Committee concluded it was unlikely that the study would meet its primary endpoint of overall survival (OS) and recommended that the study be stopped. The study was terminated in accordance with this recommendation. All sites were instructed to immediately discontinue all patients from experimental lenalidomide/placebo treatment administered either in combination with chemotherapy or as a single agent following chemotherapy discontinuation. Subsequently, Protocol Amendment 3 was issued to provide for the following:
To continue to collect information on Second Primary Malignancies (SPMs) and additional treatments for Prostate Cancer in all randomized subjects during survival follow-up.
To continue to provide docetaxel and prednisone for up to 10 cycles to subjects randomized at non-US sites who were ongoing in the CC-5013-PC-002 protocol when the decision was made to discontinue lenalidomide/placebo and who were experiencing benefit as per investigator discretion. For subjects who had exceeded 10 cycles of docetaxel and prednisone at the time of Protocol Amendment 3 approval, an additional two cycles were provided.
All references to dosing and study procedures pertaining to the safety, efficacy, and exploratory endpoints of lenalidomide/placebo were discontinued as part of Protocol Amendment 3.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
25 mg lenalidomide orally once each day on Days 1-14; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice daily on each day of the treatment cycle
Drug: Lenalidomide · Drug: Docetaxel · Drug: Prednisone
Oral placebo once each day on Days 1-14 of the treatment cycle; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice each day on each day of the treatment cycle
Drug: Docetaxel · Drug: Prednisone · Drug: Placebo
25 mg lenalidomide orally once each day on Days 1-14
Also known as: CC-5013, Revlimid
75 mg/m2 intravenous docetaxel on Day 1
Also known as: Taxotere
5 mg prednisone orally twice daily on each day of the treatment cycle
Also known as: There are multiple brand names for prednisone.
Oral placebo once each day on Days 1-14 of the treatment cycle
Overall Survival (OS)
Overall survival (OS) was the time from the date of randomization to the date of death from any cause. If no death was reported for a participant before the cut-off date for OS analysis, OS was censored at the last date at which the participant was alive. The median OS was calculated based on Kaplan-Meier estimates and corresponding 95% confidence interval (CI) was calculated using the method provided by Brookmeyer and Crowley.
Time frame: From randomization until death from any cause up to the cut-off date of 13 January 2012; up to approximately 26 months
Progression-Free Survival (PFS)
PFS was the time from randomization to disease progression, or death, whatever occurred first. Progression criteria was met by analysis of target and non-target lesions as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria. Progressive Disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters while on study or the appearance of one or more new lesions; an increase of at least 5mm as a total sum. Lymph nodes identified as target lesions (≥ 15 mm diameter in short axis) will be followed and reported by changes in diameter of short axis; or the unequivocal progression of a non-target lesion defined as an increase in the overall disease burden based on the change in non-measurable disease that is comparable in scope to the increase required to declare PD for measurable disease; Two or more new bone lesions as detected by bone scan
Time frame: From randomization until disease progression or death from any cause; up to the cut-off date of 13 Jan 2012; maximum time on study was approximately 26 months
Percentage of Participants With an Objective Response According to Response Evaluation Criteria in Solid Tumors - RECIST Version 1.1 Criteria
Objective response (OR) is defined as having complete response (CR) or partial response (PR) as best overall response based on RECIST Criteria 1.1 and defines a CR = Disappearance of all target lesions except lymph nodes (LN); LN must have a decrease in the short axis to \<10mm; PR = 30% decrease in sum of diameters of target lesions taking as reference the baseline sum diameters; Progressed Disease (PD) = 20% increase in sum of diameters of target lesions taking as a reference the smallest sum of diameters and an absolute increase of ≥5 mm; the appearance of ≥1 new lesions; Stable Disease (SD)= Neither shrinkage to qualify for PR nor increase to qualify for PD taking the smallest sum diameters on study as reference. For non-target lesions a CR = Disappearance of all non-target lesions and all LN must be non-pathological in size \<10 mm; Non-CR/Non PD: persistence of one or more non-target lesions; PD = unequivocal progression of existing non-target lesions or appearance of new ones
Time frame: From day 1 to data cut-off 13 January 2012; maximum time on study was approximately 26 months
Number of Participants With Treatment Emergent Adverse Events (AEs)
A TEAE is defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. A TESAE is defined as any serious adverse event (SAE) occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. Safety and severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0; Severity of AEs were graded (including second primary malignancies) as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5-Fatal;
Time frame: From the time from of first dose of study drug administration to 28 days after the last dose of study drug and up to the data cut off date of 13 January 2012; the maximum duration of study drug was 93 weeks for DP and 90.6 weeks for DPL
Percentage of Participants Who Received Post-Study Therapies
Percentage of Participants Who Received Post-Study Therapies for advanced Prostate Cancer.
Time frame: The date when the first consent form was signed to the last date of AE data collection;up to 5 years; up to the date of the final data analysis date of 20 April 2017
Percentage of Participants With Secondary Primary Malignancies During the Course of the Trial
Second primary malignancies were monitored as events of interest and reported as serious adverse events throughout the course of the trial.
Time frame: The date when the first consent form was signed to the last date of AE data collection; up to the date of the final data analysis date of 30 November 2016; 7 years and 19 days
Time to Onset of Secondary Primary Malignancies
Time of Onset of Secondary Primary Malignancies was considered an event of interest
Time frame: The date when the first consent form was signed to the last date of AE data collection; up to the date of the final data analysis date of 30 November 2016; 7 years and 19 days
Following a safety and efficacy data review by the Data Monitoring Committee( DMC), the trial was stopped for futility. At that time, 1059 participants had been randomized and 1046 treated with either lenalidomide plus docetaxel and prednisone or placebo plus docetaxel and prednisone. A data cutoff date of 13 January 2012 was established.
| Milestone | Docetaxel/Prednisone/Placebo (DP) | Docetaxel/Prednisone/Lenalidomide (DPL) |
|---|---|---|
| Started | 526 | 533 |
| Treated | 521 | 525 |
| Completed | 95 | 95 |
| Not completed | 431 | 438 |
| Withdrew: Adverse event | 71 | 122 |
| Withdrew: Disease progression | 103 | 89 |
| Withdrew: Withdrawal by subject | 50 | 57 |
| Withdrew: Death | 9 | 15 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Protocol violation | 9 | 2 |
| Withdrew: Sponsor decision | 102 | 78 |
| Withdrew: Clinical progression | 17 | 16 |
| Withdrew: Biochemical progression | 21 | 7 |
| Withdrew: Clinical deterioration | 7 | 14 |
| Withdrew: Subject decision/investigator discretion | 32 | 32 |
| Withdrew: Other | 8 | 3 |
Overall survival (OS) was the time from the date of randomization to the date of death from any cause. If no death was reported for a participant before the cut-off date for OS analysis, OS was censored at the last date at which the participant was alive. The median OS was calculated based on Kaplan-Meier estimates and corresponding 95% confidence interval (CI) was calculated using the method provided by Brookmeyer and Crowley.
| weeks | Docetaxel/Prednisone/Placebo (DP) | Docetaxel/Prednisone/Lenalidomide (DPL) |
|---|---|---|
| Overall Survival (OS) | NA (75.71 to NA) | 77 (64.29 to 81.71) |
PFS was the time from randomization to disease progression, or death, whatever occurred first. Progression criteria was met by analysis of target and non-target lesions as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria. Progressive Disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters while on study or the appearance of one or more new lesions; an increase of at least 5mm as a total sum. Lymph nodes identified as target lesions (≥ 15 mm diameter in short axis) will be followed and reported by changes in diameter of short axis; or the unequivocal progression of a non-target lesion defined as an increase in the overall disease burden based on the change in non-measurable disease that is comparable in scope to the increase required to declare PD for measurable disease; Two or more new bone lesions as detected by bone scan
| Weeks | Docetaxel/Prednisone/Placebo (DP) | Docetaxel/Prednisone/Lenalidomide (DPL) |
|---|---|---|
| Progression-Free Survival (PFS) | 46 (42.14 to 53.57) | 45 (38.0 to 46.14) |
Objective response (OR) is defined as having complete response (CR) or partial response (PR) as best overall response based on RECIST Criteria 1.1 and defines a CR = Disappearance of all target lesions except lymph nodes (LN); LN must have a decrease in the short axis to \<10mm; PR = 30% decrease in sum of diameters of target lesions taking as reference the baseline sum diameters; Progressed Disease (PD) = 20% increase in sum of diameters of target lesions taking as a reference the smallest sum of diameters and an absolute increase of ≥5 mm; the appearance of ≥1 new lesions; Stable Disease (SD)= Neither shrinkage to qualify for PR nor increase to qualify for PD taking the smallest sum diameters on study as reference. For non-target lesions a CR = Disappearance of all non-target lesions and all LN must be non-pathological in size \<10 mm; Non-CR/Non PD: persistence of one or more non-target lesions; PD = unequivocal progression of existing non-target lesions or appearance of new ones
| percentage of participants | Docetaxel/Prednisone/Placebo (DP) | Docetaxel/Prednisone/Lenalidomide (DPL) |
|---|---|---|
| Percentage of Participants With an Objective Response According to Response Evaluation Criteria in Solid Tumors - RECIST Version 1.1 Criteria | 24.3 | 22.1 |
A TEAE is defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. A TESAE is defined as any serious adverse event (SAE) occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. Safety and severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0; Severity of AEs were graded (including second primary malignancies) as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5-Fatal;
| participants | Docetaxel/Prednisone/Placebo (DP) | Docetaxel/Prednisone/Lenalidomide (DPL) |
|---|---|---|
| Any TEAE | 512 | 517 |
| Any TEAE related to lenalidomide or placebo | 379 | 412 |
| Any TEAE related to docetaxel/prednisone | 475 | 481 |
| Any severity grade 3-4 TEAE | 303 | 381 |
| Any serious AE (SAE) | 171 | 279 |
| Any SAE related to lenalidomide or placebo | 62 | 167 |
| Any SAE related to docetaxel/prednisone | 86 | 182 |
| Any AE causing discontinuation of lenalidomide/PBO | 82 | 150 |
| Any AE causing withdrawal of docetaxel/prednisone | 127 | 169 |
| Any TEAE leading to death | 16 | 24 |
Percentage of Participants Who Received Post-Study Therapies for advanced Prostate Cancer.
| Percentage of Participants | Docetaxel/Prednisone/Placebo (DP) | Docetaxel/Prednisone/Lenalidomide (DPL) |
|---|---|---|
| Percentage of Participants Who Received Post-Study Therapies | 70.8 | 69.0 |
Second primary malignancies were monitored as events of interest and reported as serious adverse events throughout the course of the trial.
| percentage of participants | Docetaxel/Prednisone/Placebo (DP) | Docetaxel/Prednisone/Lenalidomide (DPL) |
|---|---|---|
| Invasive Secondary Primary Malignancies | 1.3 | 1.7 |
| Non-invasive Secondary Primary Malignancies | 0.4 | 1.0 |
Time of Onset of Secondary Primary Malignancies was considered an event of interest
| months | Docetaxel/Prednisone/Placebo (DP) | Docetaxel/Prednisone/Lenalidomide (DPL) |
|---|---|---|
| Time to Onset of Secondary Primary Malignancies | 29.7 (0.6 to 48.7) | 19.7 (3.7 to 65.0) |
Collected over From first dose of study treatment to 28 days after the last dose; as of the final analysis cut-off of 20 April 2017; median overall duration of treatment was 22.1 months for DPL and 27.0 months for the DP group. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Docetaxel/Prednisone/Lenalidomide (DPL) | — | 283/525 (53.9%) | 513/525 (97.7%) |
| Docetaxel/ Prednisone/and Placebo (DP) | — | 176/521 (33.8%) | 511/521 (98.1%) |
| Event | Docetaxel/Prednisone/Lenalidomide (DPL) | Docetaxel/ Prednisone/and Placebo (DP) |
|---|---|---|
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 52/525 | 23/521 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 34/525 | 8/521 |
| NEUTROPENIABlood and lymphatic system disorders | 32/525 | 11/521 |
| PNEUMONIAInfections and infestations | 24/525 | 8/521 |
| DIARRHOEAGastrointestinal disorders | 22/525 | 5/521 |
| PYREXIAGeneral disorders | 19/525 | 6/521 |
| ANAEMIABlood and lymphatic system disorders | 18/525 | 12/521 |
| NEUTROPENIC SEPSISInfections and infestations | 15/525 | 6/521 |
| ATRIAL FIBRILLATIONCardiac disorders | 14/525 | 8/521 |
| DEHYDRATIONMetabolism and nutrition disorders | 13/525 | 4/521 |
| Event | Docetaxel/Prednisone/Lenalidomide (DPL) | Docetaxel/ Prednisone/and Placebo (DP) |
|---|---|---|
| FATIGUEGeneral disorders | 238/525 | 232/521 |
| DIARRHOEAGastrointestinal disorders | 236/525 | 204/521 |
| ALOPECIASkin and subcutaneous tissue disorders | 223/525 | 226/521 |
| NAUSEAGastrointestinal disorders | 170/525 | 153/521 |
| ANAEMIABlood and lymphatic system disorders | 154/525 | 94/521 |
| OEDEMA PERIPHERALGeneral disorders | 146/525 | 134/521 |
| CONSTIPATIONGastrointestinal disorders | 144/525 | 124/521 |
| PERIPHERAL SENSORY NEUROPATHYNervous system disorders | 99/525 | 130/521 |
| NEUTROPENIABlood and lymphatic system disorders | 125/525 | 94/521 |
| DECREASED APPETITEMetabolism and nutrition disorders | 125/525 | 105/521 |
Includes those from the Intent to Treat population (ITT). The ITT population is defined as all participants who were randomized, independent of whether they received study treatment or not.
| Age, Continuous(years) | Docetaxel/Prednisone/Placebo (DP) | Docetaxel/Prednisone/Lenalidomide (DPL) | Total |
|---|---|---|---|
| Mean | 68.4 ± 7.79 | 68.9 ± 7.98 | 68.7 ± 7.89 |
| Age, Customized(Participants) | Docetaxel/Prednisone/Placebo (DP) | Docetaxel/Prednisone/Lenalidomide (DPL) | Total |
|---|---|---|---|
| <65 years | 171 | 163 | 334 |
| > = to 65 years and < = 75years | 246 | 244 | 490 |
| >75 years | 109 | 126 | 235 |
| Sex/Gender, Customized(Participants) | Docetaxel/Prednisone/Placebo (DP) | Docetaxel/Prednisone/Lenalidomide (DPL) | Total |
|---|---|---|---|
| male | 526 | 533 | 1059 |
| female | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Docetaxel/Prednisone/Placebo (DP) | Docetaxel/Prednisone/Lenalidomide (DPL) | Total |
|---|---|---|---|
| US or Canada | 136 | 140 | 276 |
| EU or Australia | 329 | 330 | 659 |
| Rest of World (Includes 4 additional countries) | 61 | 63 | 124 |
| Race, Customized(Participants) | Docetaxel/Prednisone/Placebo (DP) | Docetaxel/Prednisone/Lenalidomide (DPL) | Total |
|---|---|---|---|
| White | 433 | 436 | 869 |
| Other or no answer | 55 | 67 | 122 |
| Black or African American | 25 | 21 | 46 |
| Asian | 8 | 6 | 14 |
| American Indian or Alaska Native | 5 | 3 | 8 |
| Weight(kilograms) | Docetaxel/Prednisone/Placebo (DP) | Docetaxel/Prednisone/Lenalidomide (DPL) | Total |
|---|---|---|---|
| Mean | 86.4 ± 16.18 | 86 ± 15.70 | 86.2 ± 15.93 |
| Height(centimeters) | Docetaxel/Prednisone/Placebo (DP) | Docetaxel/Prednisone/Lenalidomide (DPL) | Total |
|---|---|---|---|
| Mean | 174.0 ± 7.81 | 174.4 ± 7.38 | 174.2 ± 7.60 |
| Body Mass Index(kg/m^2) | Docetaxel/Prednisone/Placebo (DP) | Docetaxel/Prednisone/Lenalidomide (DPL) | Total |
|---|---|---|---|
| Mean | 28.6 ± 5.02 | 28.3 ± 4.60 | 28.4 ± 4.81 |
8 further baseline measures are reported on the registry.
Showing the first 100 of 210 sites across 21 countries. Choose a country and city above to see the rest.
Ran from Nov 2009 to primary completion in Jan 2012, 26 months.
Results were first posted in Sep 2013, 1 year 7 months after primary completion.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 26 months is below that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide